Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Ravulizumab, a novel long‐acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two randomised, open‐label, phase 3 trials in C5 inhibitor‐naïve (Study 301) and eculizumab‐experienced (Study 302) adult patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Peffault de Latour, Régis, Brodsky, Robert A., Ortiz, Stephan, Risitano, Antonio M., Jang, Jun H., Hillmen, Peter, Kulagin, Alexander D., Kulasekararaj, Austin G., Rottinghaus, Scott T., Aguzzi, Rasha, Gao, Xiang, Wells, Richard A., Szer, Jeff
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Red cells and Iron
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687070/
https://ncbi.nlm.nih.gov/pubmed/32449174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16711
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados